Falbikitug
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Falbikitug
- azd 0171
- AZD-0171
- azd0171
- Azd0171
- AZD0171
- falbikitug
- Falbikitug
- falbikitug [INN]
- FALBIKITUG [USAN]
- Falbikitug [WHO-DD]
- falbikitug inn
- falbikitug usan
- falbikitug who dd
- gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-15*07 (86.9%)--(IGHD) -IGHJ1*01(90.9%), CDR-IMGT [8.10.9] (26-33.51-60.99-107))(1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1K120, CH3 D12, L14 (CH1 K120 (215) (119-216),hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV2-24*01 (90.0%)-IGKJ2*01 (100%), CDR-IMGT [11.3.10] (27-37.55-57.94-103)) (1'-113') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa
- gamma1 heavy chain humanized 1 448 vh homo sapiens ighv3 15 07 86 9 ighd ighj1 01 90 9 cdr imgt 8 10 9 26 33 51 60 99 107 1 118 homo sapiens ighg1 01 100 g1m17 1 ch1k120 ch3 d12 l14 ch1 k120 215 119 216 hinge 1 15 217 231 ch2 232 341 ch3 d12 357 l14 359 342 446 chs 447 448 119 448 221 220 disulfide with kappa light chain humanized 1 220 v kappa homo sapiens igkv2 24 01 90 0 igkj2 01 100 cdr imgt 11 3 10 27 37 55 57 94 103 1 113 homo sapiens igkc 01 100 km3 a45 1 159 v101 197 114 220 dimer 227 227 230 230 bisdisulfide produced in chinese hamster ovary cho cells derived from the cell line cho k1 glycoform alfa
- immunoglobulin g1 anti human leukemia inhibitory factor human wistar rat monoclonal azd0171 γ1 chain disulfide with human wistar monoclonal azd0171 κ chain dimer
- immunoglobulin g1 kappa anti homo sapiens lif lif interleukin 6 family cytokine leukemia inhibitory factor humanized monoclonal antibody
- Immunoglobulin G1-kappa, anti-[Homo sapiens LIF (LIF interleukin 6 family cytokine, leukemia inhibitory factor)], humanized monoclonal antibody
- Immunoglobulin G1, anti-(human leukemia inhibitory factor) (human-Wistar rat monoclonal AZD0171 γ1-chain), disulfide with human-Wistar monoclonal AZD0171 κ-chain, dimer
- msc 1
- Msc 1
- Msc-1
- MSC-1
- CAS registry numbers
- 2740565-02-8
- ChEMBL ID
- CHEMBL5315010
- FDA ingredient codes (UNII)
- E4JL3K3CI6
- First in class
- No
- Orphan designation
- No
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- NCT04999969
- NCT05061550
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 298 $ 298''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLQESGGGLVKPGGSLRLSCAASGFTFSHAWMHWVRQAPGKGLEWVGQIKAKSDDYATYYAESVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTCWEWDLDFWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Disulfide bridges
- Sequence
- 22-98 $ 22''-98'' $ 23'-93' $ 23'''-93''' $ 140'-200' $ 140'''-200''' $ 145-201 $ 145''-201'' $ 221-220' $ 221''-220''' $ 227-227'' $ 230-230'' $ 262-322 $ 262''-322'' $ 368-426 $ 368''-426''
- Component
- Light chain
- Type
- Protein
- Sequence
- DIVMTQTPLSSPVTLGQPASISCRSSQSLLDSDGHTYLNWLQQRPGQPPRLLIYSVSNLESGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQATHAPPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (3)
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
- Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
In development for (2)
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 2